Business Description
THX Pharma
ISIN : FR0013286259
Total Employee Number:
11Compare
Compare
Traded in other countries / regions
ALTHX.France3VG.Germany IPO Date
2020-07-02Description
THX Pharma Formerly Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.7 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 0.99 | |||||
Debt-to-EBITDA | -0.76 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 36.7 | |||||
3-Year EPS without NRI Growth Rate | 40.8 | |||||
3-Year FCF Growth Rate | 57.1 | |||||
3-Year Book Growth Rate | -41.2 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.36 | |||||
9-Day RSI | 53.71 | |||||
14-Day RSI | 52.88 | |||||
3-1 Month Momentum % | 2.95 | |||||
6-1 Month Momentum % | 51.2 | |||||
12-1 Month Momentum % | 169.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.55 | |||||
Quick Ratio | 1.55 | |||||
Cash Ratio | 1.31 | |||||
Days Payable | 260.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -35.5 | |||||
Shareholder Yield % | -13.69 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -482.64 | |||||
ROA % | -47.87 | |||||
ROIC % | -90.41 | |||||
3-Year ROIIC % | 74.55 | |||||
ROC (Joel Greenblatt) % | -12446.81 | |||||
ROCE % | -180.72 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 4.42 | |||||
PB Ratio | 17.03 | |||||
Price-to-Tangible-Book | 26.62 | |||||
EV-to-EBIT | -11.57 | |||||
EV-to-EBITDA | -11.88 | |||||
EV-to-FCF | -44.19 | |||||
| Price-to-Net-Current-Asset-Value | 31.45 | |||||
| Price-to-Net-Cash | 346 | |||||
Earnings Yield (Greenblatt) % | -8.65 | |||||
FCF Yield % | -2.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
THX Pharma Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.252 | ||
| Beta | 2.2155 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 1.61 | ||
| Volatility % | 113.58 | ||
| 14-Day RSI | 52.88 | ||
| 14-Day ATR (€) | 0.182198 | ||
| 20-Day SMA (€) | 3.3645 | ||
| 12-1 Month Momentum % | 169.53 | ||
| 52-Week Range (€) | 0.96474 - 4.47 | ||
| Shares Outstanding (Mil) | 14.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
THX Pharma Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
THX Pharma Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
THX Pharma Frequently Asked Questions
What is THX Pharma(STU:3VG)'s stock price today?
The current price of STU:3VG is €3.46. The 52 week high of STU:3VG is €4.47 and 52 week low is €0.96.
When is next earnings date of THX Pharma(STU:3VG)?
The next earnings date of THX Pharma(STU:3VG) is .
Does THX Pharma(STU:3VG) pay dividends? If so, how much?
THX Pharma(STU:3VG) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Beyond Batten Disease Foundation Announces Agreement with Actelion Pharmaceuticals Ltd to Provide Drug Product for BBDF-101 | 2021-03-02 |
Articles on THX Pharma
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers